Knee Osteoarthritis Treatment: 4 Core Approaches Compared

Why Knee Osteoarthritis Treatment Matters

Knee osteoarthritis is one of the most common reasons adults consult a family physician about joint pain. Epidemiological estimates place the global burden at more than 650 million people, or roughly one in four adults aged 40 and over.

It is also a leading cause of years lived with disability. For most patients, the family physician is the first — and often the only — clinician who guides them through the options.

That guidance is harder than it looks. Patients arrive having read about injections and, increasingly, platelet-rich plasma, often driven by marketing and personal anecdote. Costs differ enormously between a home exercise programme and a course of biologic injections.

Ranking knee osteoarthritis treatment by the quality of its evidence — rather than by price, novelty, or popularity — is the useful clinical task. This review does exactly that for the four approaches patients most often ask about.

Available Approaches

The table summarises the strongest evidence for each approach. Every figure below was confirmed against a primary source retrieved for this review, with its confidence tier and a resolving reference. Sample sizes are the real values reported in each study.

Exercise therapy

Exercise has by far the deepest evidence base. The 2024 Cochrane review pooled 139 randomized trials and more than 12,000 participants, and every international guideline names structured land-based exercise a core treatment.

Against no treatment or usual care, exercise reduced pain by about 13 points on a 0–100 scale. Against a placebo or attention control — the more rigorous comparison — the reduction was about 9 points, below the 12-point threshold most patients would notice.

The certainty is low to moderate, chiefly because most trials could not blind participants. The honest reading: exercise works, its average effect is modest, and its value rests on safety, low cost, and benefits for weight and comorbidity rather than a dramatic pain reduction.

Corticosteroid injections

Intra-articular corticosteroids act fast. The 2015 Cochrane review of 27 trials found a benefit on pain and function at one to six weeks, though the evidence was low quality and the effect uncertain beyond six weeks.

The limits show up over time. In a 2-year randomized trial, triamcinolone every three months produced no better pain control than saline and was associated with significantly greater cartilage volume loss. Repeated injection is therefore a short-term tool, not a maintenance strategy.

Hyaluronic acid (viscosupplementation)

Hyaluronic acid is the most contested option. A 2022 meta-analysis restricted to large trials found its effect on pain clinically irrelevant (SMD −0.08, 95% CI −0.15 to −0.02), alongside a higher risk of serious adverse events (relative risk 1.49).

Yet the picture is not uniform. In a direct head-to-head meta-analysis, hyaluronic acid outperformed corticosteroid on pain at three and six months, and some analyses of high-molecular-weight preparations report larger effects. This heterogeneity is why guideline bodies reach opposite conclusions, as the next section describes.

Platelet-rich plasma (PRP)

PRP is the newest and most heavily marketed approach. In pooled network analyses it ranks highest of all injectables: one network meta-analysis of 48 studies gave PRP the top ranking for pain and function at six months or more.

The most rigorous single trial tells a different story. In the placebo-controlled RESTORE trial, leukocyte-poor PRP was no better than saline for symptoms or cartilage at 12 months, with 29 of 31 secondary outcomes showing no difference. PRP preparations are also non-standardized, which limits how far any pooled ranking can be trusted.

Quality and Consistency of the Evidence

Strength of evidence varies sharply by approach and by the outcome examined. The ratings below reflect trial quality, consistency, and the gap between pooled estimates and the most rigorous individual trials.

• Exercise (moderate). A very large, consistent randomized base of 139 trials, but effect magnitude versus placebo is uncertain and most trials were unblinded, lowering certainty.
• Corticosteroid, short-term (moderate to low). Consistent short-term benefit across 27 trials, but the underlying evidence was rated low quality and heterogeneous.
• Corticosteroid, structure and long-term (low). A single rigorous trial signals harm to cartilage and no lasting pain benefit; this needs confirmation but is a genuine concern.
• Hyaluronic acid (mixed). High between-study heterogeneity; the effect shrinks toward null when analysis is limited to large, low-risk-of-bias trials, which is why guidelines conflict.
• PRP (low). Substantial heterogeneity and non-standardized preparations; the top pooled ranking is not supported by the best placebo-controlled trial.

Two patterns recur. First, effects are largest in smaller or unblinded studies and shrink in rigorous ones. Second, the newer the therapy, the wider the gap between marketing claims and confirmed benefit.

Practical Implications

The evidence supports leading with exercise, weight management, and education for essentially every patient. This tier carries the highest certainty, the lowest cost, and the fewest harms, and it underpins every major guideline.

A corticosteroid injection is reasonable for a painful flare or to help a patient participate in rehabilitation. The evidence does not support repeated injections as an ongoing maintenance plan, given the cartilage signal and loss of benefit over time.

PRP and hyaluronic acid call for candid, shared decision-making. Both are costly, the evidence is mixed to weak, and guideline bodies disagree; patients deserve to hear that the popular ranking and the evidence ranking are not the same.